After attending the Summit and the CME sessions, participants should be able to:

1. General Session – Prostate Cancer Advocacy 
   • Describe and promote the need for active surveillance in men with prostate cancer.  
   • Explain the effectiveness of the United States Preventative Services Task Force’s change to the grade recommendation for prostate cancer screening. 
   • Evaluate the United States Preventive Services Task Force Guidelines and existing data.
   • Discuss potential collaboration with state legislatures, patient advocacy communities and others to draft model language on improving prostate cancer screening coverage.
2. General Session – Research
   • Discuss the differences in the behavior of prostate cancer in African American men and the need to advocate for increased research.
   • Evaluate the need for increased clinical research studies of high at-risk populations subjected to health care disparities. 
3. Regulatory Burdens to Care
   • Identify the efficiencies in electronic health records.
   • Discuss the role of step therapy and prior authorization, its impact on personalized medicine, and its barriers to care and physician treatment.
4. Transgendered Care
   • Describe advocacy issues facing pediatric urology, transgendered care and sex development as a whole.
   • Explain the current advocacy efforts regarding disorders of sex development, and transgendered care at the state and local levels.
   • Outline the best practices in gender medicine, including gender-affirming surgery. 
5. Access to Rural Care
   • Describe and determine the role of nurse practitioners and urologists in smaller clinic versus academic setting.
   • Explain and measure the ability to find appropriately trained physicians to treat adults with congenital conditions.
   • Describe the growing concern for Medicare beneficiaries in rural America with regard to the aging urologic workforce, and increased centralization of urologists in larger cities.
6. Stark Law under MACRA
   • Explain how Stark Reform works to allow independent urologic practices to thrive under MACRA while maintaining the In-Office Ancillary Service Exception (IOASE).
   • Analyze and apply regulatory implementation of MACRA.
   • Examine patient access to physician administered cancer therapy through Medicare Part B.
7. Opioids
   • Summarize how electronic residency application services’ (ERAS) protocolized post-surgery care pathways for cystectomy/nephrectomy: 1) decrease opiate use post-operatively, 2) increase post-operative care quality and 3) reduce post-operative care costs. 
8. Veterans Healthcare Roundtable
   • Examine veteran’s care regarding fertility and prostate cancer.
9. Fertility Care and Coverage 
   • Evaluate sexual and reproductive health of veterans and the ability to find appropriately trained physicians to treat adults with congenital conditions.
   • Explain the current state advocacy efforts in mandating insurance coverage for fertility preservation.
10. Access to Care – Workforce 
    • Evaluate the urology work force, and describe where shortages exist. 
    • Discuss how to integrate Advanced Practice Providers (APPs) into urologic practices; and how employing APPs can make a positive impact on patient access and care. 
11. Prescription Drug Price Negotiation 
    • Explain the need for drug price controls to be lifted to allow Medicare to negotiate with pharmaceutical industry in order to provide discounted pricing for some patients.   
12. Advanced Payment Models/Value Based Payments
    • Evaluate the status of advanced APM’s in urology, 
    • Assess the need for value-based payments in urologic practices. 
    • Evaluate and determine the benefits of value-based care in the American healthcare system.